Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lacidofil
- Development stage
- Phase 4
- Lead developer
- Lallemand Health Solutions
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Intravaginal
01
Overview
Lacidofil is a probiotic preparation that contains a combination of two specific strains of lactic acid bacteria: *Lactobacillus rhamnosus* R0011 (also referred to as *Lacticaseibacillus rhamnosus* R0011) and *Lactobacillus helveticus* R0052. [1, 2, 4, 14] It is formulated to support gut health and has been investigated in numerous clinical studies for various indications. Research suggests its efficacy in the prevention of antibiotic-associated diarrhea, as an adjunct therapy for *Helicobacter pylori* eradication, and in the management of pediatric gastroenteritis. [4, 7, 16] Studies have also shown potential benefits in treating atopic dermatitis in children, where it was associated with clinical improvement and a reduced need for corticosteroids. [17] The mechanism of action is believed to involve modulating the gut microbiota, competing with pathogens, and regulating local and systemic immune and inflammatory responses. [4, 7, 17]
- Brand names
- LacidofilLacidofil cap®Lacidofil® STRONG
- Other names
- Lallemand IBS-D probiotic formulation3-strain probiotic formulation (Lallemand)
Beyond the preview
Go deeper on Lacidofil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lacidofil.